ICON Launches New Medical Imaging Solution for Early Phase Trials
News Oct 25, 2012
ICON plc, has announced the launch of a new medical imaging solution tailored to the unique requirements of early phase trials.
This new solution incorporates streamlined processes and procedures to maximize the information collected from image data and to ensure that this information is processed rapidly in line with the shorter timelines and requirements of early-phase research.
Enhanced decision making is then enabled by MIRA™, ICON’s image management system, which standardizes data from all imaging formats and allows for centralized analysis and interpretation of data.
Driving this innovation is a team of scientific and regulatory experts with deep imaging and early-phase experience to help sponsors make critical decisions about their compounds faster.
“PET, volumetrics, advanced CT and MRI are increasingly being used in early phase research which has created a demand for more tailored imaging solutions for early phase trials,” commented Ted Gastineau, President, ICON Medical Imaging.
Gastineau continued, “We have developed a unique and cost-effective solution that provides true insight to the data generated from imaging technologies and helps clients decide earlier about the future success of a drug.”
ICON Medical Imaging’s early phase group will be led by Dr. James Conklin, Senior Vice President, Medical and Scientific Affairs and Dr. Valerie Treyer, Director, Medical and Scientific Affairs, who together bring over 45 years of experience in the management of medical image data used in clinical trials.
The group will work closely with ICON Development Solutions which provides a full range of early-phase services, including clinical pharmacology, bioanalytical, PK/PD modelling and simulation, and Clinical Pharmacodynamic Models for early indications of drug efficacy.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018